LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Predicting Thrombosis Risk in SLE Patients by Monitoring Blood Levels of Hydroxychloroquine

By LabMedica International staff writers
Posted on 12 Jan 2021
Print article
Image: Ball-and-stick model of a hydroxychloroquine molecule (Photo courtesy of Wikimedia Commons)
Image: Ball-and-stick model of a hydroxychloroquine molecule (Photo courtesy of Wikimedia Commons)
Risk of developing a blood clot (thrombosis) by patients suffering from systemic lupus erythematosus can be predicted by monitoring levels of hydroxychloroquine in the blood.

Systemic lupus erythematosus (SLE) is an autoimmune disease triggered by genetic and environmental factors in which the body's immune system mistakenly attacks healthy tissue in many parts of the body. Symptoms vary and may be mild to severe. Common symptoms include painful and swollen joints, fever, chest pain, hair loss, mouth ulcers, swollen lymph nodes, fatigue, and a red rash which is most commonly on the face. Often there are periods of illness, called flares, and periods of remission during which there are few symptoms. The anti-malaria drug hydroxychloroquine (HCQ) has a primary role in the prophylaxis and treatment of systemic lupus erythematosus (SLE) and may be protective against thrombosis in SLE.

Investigators at Johns Hopkins University (Baltimore, MD, USA) examined the usefulness of HCQ blood monitoring in predicting thrombosis risk in a longitudinal SLE cohort. For this study, the investigators used liquid chromatography‐tandem mass spectrometry to measure levels of HCQ in EDTA whole blood samples taken from 739 patients with SLE.

Results revealed that clotting occurred in 38 patients (5.1%). Average HCQ blood levels were lower in patients who developed clots, and clotting rates were reduced by 12% for every 200 nanograms per milliliter increase in the most recent HCQ blood level. Thrombotic events were reduced by 69% in patients with mean HCQ blood levels greater than 1068 nanograms per milliliter versus less than 648 nanograms per milliliter.

Low HCQ blood levels were associated with thrombotic events in SLE. "Hydroxychloroquine blood levels can be used to monitor adherence, benefits, and risks in lupus," said first author Dr. Michelle Petri, professor of medicine at Johns Hopkins University.

The hydroxychloroquine paper was published in the January 5, 2021, online edition of the journal Arthritis & Rheumatology.

Related Links:
Johns Hopkins University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more